[HTML][HTML] Effect of treatment with tabalumab, a B cell–activating factor inhibitor, on highly sensitized patients with end-stage renal disease awaiting transplantation
MA Mujtaba, WJ Komocsar, E Nantz… - American Journal of …, 2016 - Elsevier
B cell–activation factor (BAFF) is critical for B cell maturation. Inhibition of BAFF represents
an appealing target for desensitization of sensitized end-stage renal disease (ESRD)
patients. We conducted a Phase 2a, single-arm, open-label exploratory study investigating
the effect of tabalumab (BAFF inhibitor) in patients with ESRD and calculated panel reactive
antibodies (cPRAs)> 50%. The treatment period duration was 24 weeks. Eighteen patients
received tabalumab, at doses of 240-mg subcutaneous (SC) at Week 0 followed by 120-mg …
an appealing target for desensitization of sensitized end-stage renal disease (ESRD)
patients. We conducted a Phase 2a, single-arm, open-label exploratory study investigating
the effect of tabalumab (BAFF inhibitor) in patients with ESRD and calculated panel reactive
antibodies (cPRAs)> 50%. The treatment period duration was 24 weeks. Eighteen patients
received tabalumab, at doses of 240-mg subcutaneous (SC) at Week 0 followed by 120-mg …